An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis

Journal of Internal Medicine

Volumn 260, Issue 6, 2006, Pages 577-585

  Agarwal, A K ^a,h   Silver, M R ^b   Reed, J E ^c   Dhingra, R K ^d   Liu, W ^e,g   Varma, N ^f   Stehman Breen, C ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c Nephrology Associates   (United States)

^d WRIGHT STATE UNIVERSITY   (United States)

^e Biostatistics   (United States)

^f AMGEN INC   (United States)

^g ELAN PHARMACEUTICALS   (United States)

^h N210 Means Hall ^*  (United States)

Author keywords

Anaemia; Chronic kidney disease; Darbepoetin alfa; Haemoglobin

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE MONITORING; CELLULITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; GOUT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; LEG EDEMA; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHINOPHARYNGITIS; SAMPLE SIZE; SINGLE BLIND PROCEDURE; THERAPY EFFECT; TITRIMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; ANEMIA; CHRONIC DISEASE; COLONY-STIMULATING FACTORS; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33750501617     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01723.x     Document Type: Article

References (26)

1. Perlman RL, Finkelstein FO, Liu L et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 2005; 45: 658-66.
2. Gerson A, Hwang W, Fiorenza J et al. Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 2004; 44: 1017-23.
3. Odden MC, Whooley MA, Shlipak MG. Association of chronic kidney disease and anemia with physical capacity: the heart and soul study. J Am Soc Nephrol 2004; 15: 2908-15.
4. Muntner P, He J, Astor BC, Folsom AR, Coresh, J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529-38.
5. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003; 14: 2919-25.
6. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan WM. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003; 64: 610-15.
7. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-34.
8. Silverberg D, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18: 141-6.
9. Fink JC, Blahut SA, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37: 348-55.
10. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-60.
11. Dean BB, Dylan M, Gano AJ, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21: 981-7.
12. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alpha has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31: 290-9.
13. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414-21.
14. Hertel J, Locay H, Scarlata D, Jackson L, Parthikanti R, Audhya P. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from Simplify the Treatment of Anemia with Aranesp (STAAR). Am J Nephrol 2006; 26: 149-56.
15. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106-11.
16. Toto RD, Pichette V, Navarro J et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004; 24: 453-60.
17. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005; 63: 327-34.
18. Hertel JEW, Locay HR, Scarlata D, Parthikanti R, Audhya P. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006; 81: 1188-94.
19. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37: S182-238.
20. Levey AS, Greene T, Kusek JW, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.
21. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 2001; 10: 785-92.
22. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley and Sons, 1973.
23. Hoggard J, Crouch T, McMurray S, Levine M, Parthikanti R, Scarlata D, Audhya P. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 2006; 22: 2023-30. doi: 10.1185/030079906X148283.
24. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005; 20: CD003266.
25. Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-54.
26. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307-35 (discussion 2306).